Takeda has completed a $6-billion deal ($4 billion upfront and $2 billion in milestone payments) to acquire Nimbus Lakshmi, a subsidiary of Nimbus Therapeutics, a Cambridge, Massachusetts-based clinical-stage bio/pharmaceutical company. The companies had announced the acquisition in December 2022. 

The lead asset from Nimbus Lakshmi is an autoimmune drug candidate (now TAK-279), in late-stage development for treating multiple autoimmune diseases. The company recently completed Phase IIb studies in psoriasis, and the drug is expected to enter Phase III studies in psoriasis in 2023. The drug is also in Phase IIb studies for active psoriatic arthritis. Takeda says it plans to further evaluate the drug candidate for the treatment of inflammatory bowel disease and other autoimmune diseases.  

With the closing of the transaction, Takeda will pay Nimbus $4 billion upfront and make two milestone payments of $1 billion each upon TAK-279 achieving annual net sales of $4 billion and $5 billion, respectively.  

Source: Takeda